Business Wire

Vektor Medical to Present Positive Results from vMap Clinical Validation Study Showing 97.3% Mapping Accuracy for Atrial and Ventricular Arrhythmias

Pre-specified performance goals were used for statistical comparisons. The study used existing data from successful ablation procedures to identify the arrhythmia source location, then sent the ...
Morningstar

Vektor Medical Receives FDA 510(k) Clearance Adding Atrial Flutter Mapping, Enhanced Connectivity and New Integration Capabilities to Next-Generation vMap

Vektor Medical Receives FDA 510(k) Clearance Adding Atrial Flutter Mapping, Enhanced Connectivity and New Integration Capabilities to Next-Generation vMap Clearance Expands vMap’s Non-Invasive Mapping ...
Morningstar

Vektor Medical Secures CE Mark for vMap, Bringing the Benefits of Non-Invasive Arrhythmia Mapping to Europe | Morningstar

Vektor Medical, a medical technology company transforming cardiac arrhythmia care, announced it has received CE Mark for the vMap® System, a non-invasive tool developed with AI that transforms ...
Business Wire

vMap™’s Role in Optimizing Non-Invasive Radio-Ablation Therapy presented at ACC.21 and THRS 2021

CARLSBAD, Calif.--(BUSINESS WIRE)--Vektor Medical, Inc. announced that a dual-center study reports that vMap™, as part of a new, non-invasive workflow, improved efficiency and precision for ...
Pharmabiz

Vektor Medical receives US FDA 510(k) clearance for its next-generation vMap technology to enhance connectivity

Vektor Medical, a medical technology company headquartered in San Diego redefining how arrhythmias are understood and treated, announced it has received the US Food and Drug Administration 510(k) ...